243 related articles for article (PubMed ID: 17996253)
21. Therapeutic approach by Aloe vera in experimental model of multiple sclerosis.
Mirshafiey A; Aghily B; Namaki S; Razavi A; Ghazavi A; Ekhtiari P; Mosayebi G
Immunopharmacol Immunotoxicol; 2010 Sep; 32(3):410-5. PubMed ID: 20233107
[TBL] [Abstract][Full Text] [Related]
22. Treatment with metallothionein prevents demyelination and axonal damage and increases oligodendrocyte precursors and tissue repair during experimental autoimmune encephalomyelitis.
Penkowa M; Hidalgo J
J Neurosci Res; 2003 Jun; 72(5):574-86. PubMed ID: 12749022
[TBL] [Abstract][Full Text] [Related]
23. Future neuroprotective strategies.
Sättler MB; Bähr M
Exp Neurol; 2010 Sep; 225(1):40-7. PubMed ID: 19716365
[TBL] [Abstract][Full Text] [Related]
24. Increased thrombin inhibition in experimental autoimmune encephalomyelitis.
Beilin O; Karussis DM; Korczyn AD; Gurwitz D; Aronovich R; Hantai D; Grigoriadis N; Mizrachi-Kol R; Chapman J
J Neurosci Res; 2005 Feb; 79(3):351-9. PubMed ID: 15605378
[TBL] [Abstract][Full Text] [Related]
25. Pathological findings in rats with experimental allergic encephalomyelitis.
Dong M; Liu R; Guo L; Li C; Tan G
APMIS; 2008 Nov; 116(11):972-84. PubMed ID: 19132994
[TBL] [Abstract][Full Text] [Related]
26. Combined therapy with methylprednisolone and erythropoietin in a model of multiple sclerosis.
Diem R; Sättler MB; Merkler D; Demmer I; Maier K; Stadelmann C; Ehrenreich H; Bähr M
Brain; 2005 Feb; 128(Pt 2):375-85. PubMed ID: 15601662
[TBL] [Abstract][Full Text] [Related]
27. Hematopoietic stem cell transplantation in multiple sclerosis: experimental evidence to rethink the procedures.
Karussis D; Slavin S
J Neurol Sci; 2004 Aug; 223(1):59-64. PubMed ID: 15261562
[TBL] [Abstract][Full Text] [Related]
28. Targeting the tetraspanin CD81 blocks monocyte transmigration and ameliorates EAE.
Dijkstra S; Kooij G; Verbeek R; van der Pol SM; Amor S; Geisert EE; Dijkstra CD; van Noort JM; Vries HE
Neurobiol Dis; 2008 Sep; 31(3):413-21. PubMed ID: 18586096
[TBL] [Abstract][Full Text] [Related]
29. The translation of drug efficacy from in vivo models to human disease with special reference to experimental autoimmune encephalomyelitis and multiple sclerosis.
Bolton C
Inflammopharmacology; 2007 Oct; 15(5):183-7. PubMed ID: 17943249
[TBL] [Abstract][Full Text] [Related]
30. Spatial diversity of blood-brain barrier alteration and macrophage invasion in experimental autoimmune encephalomyelitis: a comparative MRI study.
Ladewig G; Jestaedt L; Misselwitz B; Solymosi L; Toyka K; Bendszus M; Stoll G
Exp Neurol; 2009 Nov; 220(1):207-11. PubMed ID: 19733560
[TBL] [Abstract][Full Text] [Related]
31. Sequential impact of tiazofurin and ribavirin on the enzymic program of the bone marrow.
Prajda N; Hata Y; Abonyi M; Singhal RL; Weber G
Cancer Res; 1993 Dec; 53(24):5982-6. PubMed ID: 7903199
[TBL] [Abstract][Full Text] [Related]
32. Immunoglobulins treatment in multiple sclerosis and experimental autoimmune encephalomyelitis.
Achiron A; Miron S
Mult Scler; 2000 Oct; 6 Suppl 2():S6-8; discussion S33. PubMed ID: 11188777
[TBL] [Abstract][Full Text] [Related]
33. Early macrophage MRI of inflammatory lesions predicts lesion severity and disease development in relapsing EAE.
Brochet B; Deloire MS; Touil T; Anne O; Caillé JM; Dousset V; Petry KG
Neuroimage; 2006 Aug; 32(1):266-74. PubMed ID: 16650776
[TBL] [Abstract][Full Text] [Related]
34. The selective Rho-kinase inhibitor Fasudil is protective and therapeutic in experimental autoimmune encephalomyelitis.
Sun X; Minohara M; Kikuchi H; Ishizu T; Tanaka M; Piao H; Osoegawa M; Ohyagi Y; Shimokawa H; Kira J
J Neuroimmunol; 2006 Nov; 180(1-2):126-34. PubMed ID: 16996142
[TBL] [Abstract][Full Text] [Related]
35. Calcium channel blockers ameliorate disease in a mouse model of multiple sclerosis.
Brand-Schieber E; Werner P
Exp Neurol; 2004 Sep; 189(1):5-9. PubMed ID: 15296830
[TBL] [Abstract][Full Text] [Related]
36. Soluble egg antigen from Schistosoma japonicum modulates the progression of chronic progressive experimental autoimmune encephalomyelitis via Th2-shift response.
Zheng X; Hu X; Zhou G; Lu Z; Qiu W; Bao J; Dai Y
J Neuroimmunol; 2008 Feb; 194(1-2):107-14. PubMed ID: 18207251
[TBL] [Abstract][Full Text] [Related]
37. Neuroprotection without immunomodulation is not sufficient to reduce first relapse severity in experimental autoimmune encephalomyelitis.
Hasseldam H; Johansen FF
Neuroimmunomodulation; 2010; 17(4):252-64. PubMed ID: 20203531
[TBL] [Abstract][Full Text] [Related]
38. Intravenous immunoglobulin treatment of multiple sclerosis and its animal model, experimental autoimmune encephalomyelitis.
Humle Jorgensen S; Sorensen PS
J Neurol Sci; 2005 Jun; 233(1-2):61-5. PubMed ID: 15949496
[TBL] [Abstract][Full Text] [Related]
39. Phenytoin protects central axons in experimental autoimmune encephalomyelitis.
Black JA; Waxman SG
J Neurol Sci; 2008 Nov; 274(1-2):57-63. PubMed ID: 18485368
[TBL] [Abstract][Full Text] [Related]
40. Treatment with rapamycin ameliorates clinical and histological signs of protracted relapsing experimental allergic encephalomyelitis in Dark Agouti rats and induces expansion of peripheral CD4+CD25+Foxp3+ regulatory T cells.
Donia M; Mangano K; Amoroso A; Mazzarino MC; Imbesi R; Castrogiovanni P; Coco M; Meroni P; Nicoletti F
J Autoimmun; 2009 Sep; 33(2):135-40. PubMed ID: 19625166
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
